Brief: Transgene Presents Additional Phase I Data With TG4050

Transgene SA

06/06/2022 07:06

June 6 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE PRESENTED ADDITIONAL PHASE I DATA WITH TG4050
(MYVAC®
PLATFORM) AT ASCO 2022
    * INFORMATION WE GATHER FROM TWO ONGOING PHASE I STUDIES
WILL BE
PIVOTAL IN DESIGNING PHASE II TRIAL OF TG4050 WHICH COULD START
AS EARLY AS 2023
    * THESE ADDITIONAL POSITIVE INITIAL DATA, INCLUDING
MOLECULAR
(CTDNA) RESPONSE, HAVE BEEN GENERATED FROM FIRST PATIENTS WITH
OVARIAN CANCER AND HPV-NEGATIVE HEAD AND NECK CANCER ENROLLED IN
TWO ONGOING PHASE I TRIALS ASSESSING TG4050

Source text for Eikon:  ID:nBw3lCWH8a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))